NCT00849667 2022-12-30
Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse
Morphotek
Phase 3 Terminated
Clinical Trials
8 trialsNCT01218516 2020-08-20
A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung
Morphotek
Phase 2 Completed
NCT01049061 2020-06-11
A Study of MORAb-003 in Patients With Solid Tumor
Eisai Inc.
Phase 1 Completed
NCT00738699 2017-03-30
FAR-122
Morphotek
Phase 2 Terminated
NCT00318370 2015-09-09
Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy
Morphotek
Phase 2 Completed
NCT01004380 2014-07-17
Safety Study of Farletuzumab, Carboplatin and Pegylated Liposomal Doxorubicin (PLD) to Treat Platinum-sensitive Ovarian Cancer
Morphotek
Phase 1 Completed
NCT00428766 2013-11-06
Safety, Tolerability and Pharmacokinetics of MORAb-003 in Subjects With Advanced Ovarian Cancer
Morphotek
Phase 1 Completed
NCT01203618 2013-11-04
Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas
Morphotek
Phase 2 Withdrawn